Patents by Inventor Lothar Kanz

Lothar Kanz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide for triggering an immune reaction against tumor cells
    Patent number: 7528224
    Abstract: The invention relates to a peptide for triggering an immune response to tumor cells. Said peptide has an optionally modified fragment of the protein that is encoded by the gene MUC-1. Said protein triggers an HLA-A2-restricted immune response.
    Type: Grant
    Filed: May 1, 2006
    Date of Patent: May 5, 2009
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Peter Brossart, Stefan Stevanovic, Wolfram Brugger, Lothar Kanz, Hans Georg Rammensee
  • Peptide for triggering an immune reaction against tumor cells
    Patent number: 7087712
    Abstract: The invention relates to a peptide for triggering an immune response to tumor cells. Said peptide has an optionally modified fragment of the protein that is encoded by the gene MUC-1. Said protein triggers an HLA-A2-restricted immune response.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: August 8, 2006
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Peter Brossart, Stefan Stevanovic, Wolfram Brugger, Lothar Kanz, Hans-Georg Rammensee
  • Process for preparing dendritic cells, cells thus produced and containers for carrying out this process
    Patent number: 5866115
    Abstract: Dendritic cells are of interest therapeutically as antigen-presenting cells. A process is disclosed in which peripheral blood cells are first isolated and the CD 34 antigen-expressing blood progenitor cells which they contain are then enriched. These enriched cells are expanded ex-vivo using a combination of haematopoietic growth factors and cytokines. Over a period of 10-20 days, they give rise, in particular to dendritic cells which, where appropriate, can be purified still further. These cells are functionally active with regard to the ability to present antigen.
    Type: Grant
    Filed: October 11, 1996
    Date of Patent: February 2, 1999
    Assignee: Klinikum Der Albert-Ludwigs-Universitat Freiburg
    Inventors: Lothar Kanz, Wolfram Brugger, Reinhard Henschler, Gabriele Kohler, Hans-Eckart Schaefer, Albrecht Lindemann, Roland Mertelsmann, Andreas Mackensen, Paul Fisch, Birgit Herbst
  • CD34+ peripheral blood progenitor cells obtained by ex vivo expansion
    Patent number: 5541103
    Abstract: Patients suffering from certain types of cancer are treated by high-dose chemotherapy. In order to allow a recovery a process for the ex vivo expansion of peripheral blood progenitor cells is described, wherein CD 34.sup.+ -cells are enriched and cultivated in a medium comprising IL-1, IL-3, IL-6, EPO and SCF. The ex vivo expanded peripheral blood progenitor cells can be administered to cancer patients after chemotherapy.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 30, 1996
    Assignee: Klinikum der Albert-Ludwigs-Universitat Freiburg
    Inventors: Lothar Kanz, Wolfram Brugger, Roland Mertelsmann
  • Ex vivo expansion of peripheral blood progenitor cells
    Patent number: 5472867
    Abstract: Patients suffering from certain types of cancer are treated by high-dose chemotherapy. In order to allow a recovery a process for the ex vivo expansion of peripheral blood progenitor cells is described, wherein CD 34.sup.+ -cells are enriched and cultivated in a medium comprising IL-1, IL-3, IL-6, EPO and SCF. The ex vivo expanded peripheral blood progenitor cells can be administered to cancer patients after chemotherapy.
    Type: Grant
    Filed: September 29, 1993
    Date of Patent: December 5, 1995
    Assignee: Klinkum der Albert-Ludwigs-Universitat Freiberg
    Inventors: Lothar Kanz, Woefram Brugger, Roland Mestepsmann